AstraZeneca (AZN) and Daiichi Sankyo said Monday that an interim analysis of a phase III trial showed that Enhertu combined with pertuzumab significantly improved progression-free survival in a certain type of breast cancer, compared with standard of treatment.
The progression-free survival benefit was seen across all pre-specified patient subgroups treated with the combination.
Although the key secondary endpoint of overall survival was not mature at the time of the analysis, interim data showed an early trend favoring the Enhertu combination, compared with the standard of treatment, the companies said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。